Last updated: September 7, 2026
Dorzagliatin is a first-in-class glucokinase activator developed by Hua Medicine for type 2 diabetes. China approved the drug in 2022 under the brand name HMS5552, making it the first glucokinase activator approved globally. Its commercial opportunity depends on proving durable glucose control, expanding use beyond newly diagnosed patients, and obtaining approvals outside China. The U.S. program remains the primary value inflection point.
What is the current development status of dorzagliatin?
Dorzagliatin is an oral, small-molecule glucokinase activator that targets glucokinase in the liver, pancreas and other glucose-sensing tissues. The mechanism is designed to improve glucose-dependent insulin secretion and hepatic glucose utilization without directly replacing insulin.
| Development item |
Status |
| Active ingredient |
Dorzagliatin, also known as HMS5552 |
| Developer |
Hua Medicine |
| Drug class |
Glucokinase activator |
| Initial indication |
Type 2 diabetes |
| Approved market |
China |
| China approval |
September 2022 |
| Commercial brand |
HuaTangNing |
| Dose |
75 mg orally twice daily |
| Main pivotal programs |
SEED and DAWN |
| U.S. regulatory status |
Investigational; no U.S. approval |
| European approval |
No approval publicly established through June 2024 |
| Regulatory exclusivity |
China approval-based protections; no U.S. NCE exclusivity because the product is not FDA-approved |
China approved dorzagliatin for adults with type 2 diabetes who have inadequate glycemic control through diet and exercise. The approval covers patients with relatively recent disease onset and patients who remain uncontrolled after metformin monotherapy, according to Hua Medicine’s regulatory disclosures and published clinical data (Hua Medicine, 2022; Wang et al., 2022).
What did the pivotal clinical trials show?
The SEED study evaluated dorzagliatin in treatment-naive patients with type 2 diabetes. The DAWN study evaluated patients inadequately controlled on metformin. Both were randomized, double-blind, placebo-controlled Phase 3 trials.
Published results showed clinically meaningful HbA1c reductions at 24 weeks, with a generally low risk of hypoglycemia and no requirement for glucose-dependent dose titration. The principal commercial question is durability. Glucokinase activation can lose effect if beta-cell function is substantially impaired, which may limit use in advanced type 2 diabetes.
Dorzagliatin’s clinical profile differs from sulfonylureas and insulin because its mechanism is intended to preserve glucose responsiveness. That distinction could support use earlier in the treatment pathway, but it must translate into sustained real-world control and acceptable pricing.
What is the FDA status of dorzagliatin?
Dorzagliatin is not approved by the U.S. Food and Drug Administration. Hua Medicine has pursued a U.S. development strategy, but the drug requires adequate U.S.-specific clinical evidence before an NDA can support approval.
The key U.S. regulatory issues are:
- Confirmation of efficacy in the U.S. type 2 diabetes population.
- Long-term cardiovascular and safety characterization.
- Durability of HbA1c reduction.
- Evidence supporting positioning alongside metformin, GLP-1 receptor agonists, SGLT2 inhibitors and insulin.
- Commercial differentiation against established low-cost generic therapies.
The absence of FDA approval means dorzagliatin has no U.S. Orange Book listing, no U.S. Paragraph IV litigation pathway and no U.S. Hatch-Waxman market exclusivity period. Any U.S. launch would require completion of the applicable clinical and regulatory program.
What patents protect dorzagliatin?
Dorzagliatin is protected through a portfolio covering the active compound, pharmaceutical compositions, therapeutic use and manufacturing-related subject matter. Public company disclosures identify patent protection in China and other jurisdictions, but the commercial value of the estate depends on claim scope, granted status and enforceability in each country.
| Protection category |
Commercial relevance |
| Compound patents |
Core protection against chemical copies of dorzagliatin |
| Composition patents |
Protection for tablets, excipients and dosage forms |
| Method-of-use patents |
Potential coverage for treating type 2 diabetes and patient subgroups |
| Manufacturing patents |
Can increase the cost and complexity of non-infringing production |
| Regional patent families |
Determine protection in China, the U.S., Europe and other markets |
Hua Medicine has stated that its intellectual-property estate extends beyond China. The company also reports patent filings relating to dorzagliatin’s chemical structure, medical use and formulation. Patent term and enforceability should be assessed family by family because priority dates, national-stage prosecution and granted claims can differ.
When does dorzagliatin lose patent exclusivity?
A single global expiration date cannot be assigned to dorzagliatin. The relevant dates depend on the patent family, jurisdiction, patent-term adjustments, supplementary protection certificates and any patent-term extensions.
The China commercial period is likely to be influenced by:
- Core compound patent expiry.
- Later-filed formulation and treatment patents.
- China’s patent-term compensation rules.
- Regulatory data protection, if applicable.
- Litigation outcomes involving generic or competing GKA products.
The U.S. expiry analysis is less developed because dorzagliatin lacks FDA approval and therefore has no Orange Book patent listing. If approved, Hua Medicine would need to list relevant patents in the Orange Book. Later patents could protect a formulation or method of use but would not necessarily prevent all generic competition after core compound protection expires.
What is the Orange Book status of dorzagliatin?
Dorzagliatin has no Orange Book status because FDA approval has not been granted. Consequently:
- No U.S. listed drug reference product exists.
- No Orange Book patent numbers are listed.
- No 30-month stay can arise from a Paragraph IV certification.
- No first-filer 180-day generic exclusivity is available.
- U.S. generic launch timing cannot currently be calculated under Hatch-Waxman rules.
If Hua Medicine files a U.S. NDA and receives approval, the company could list patents covering the drug substance, formulation, method of use and approved conditions of use. The resulting litigation risk would depend on which patents are listed and whether a generic applicant challenges them.
How strong is the dorzagliatin patent estate?
The patent estate appears commercially meaningful but is not yet fully de-risked. The strongest protection is expected to come from the compound and composition families. Method-of-use patents may extend the estate but usually offer narrower enforcement because they depend on the generic product’s labeling and actual use.
Strength factors
- First-mover position in glucokinase activators.
- Patent families filed in major pharmaceutical markets.
- Multiple possible protection layers beyond the basic chemical compound.
- Potential difficulty reproducing the original manufacturing process at commercial scale.
- Regulatory and clinical barriers that remain after patent expiry.
Weakness factors
- The core mechanism has been studied by several companies, increasing freedom-to-operate complexity.
- Secondary patents may face obviousness or written-description challenges.
- Generic applicants could pursue non-infringing formulations.
- China’s price-control and centralized-procurement systems can reduce the economic value of remaining patent life.
- A treatment patent may not prevent off-label or alternative-label use after compound expiry.
The estate should be rated as moderate to strong for China commercialization, but its global strength depends on granted claims and the outcome of U.S. and European prosecution.
What patent litigation affects dorzagliatin?
No major public U.S. Paragraph IV litigation involving dorzagliatin had been established through June 2024 because the drug had not received FDA approval or an Orange Book listing.
In China, commercial exposure is more likely to arise from:
- Patent validity challenges by generic manufacturers.
- Administrative patent disputes.
- Judicial infringement actions over compound or formulation claims.
- Competition from other glucokinase activators.
- Regulatory applications filed before expiry of relevant patents.
The absence of reported high-profile litigation does not establish freedom from challenge. Chinese generic manufacturers can contest patent validity or seek launch strategies based on claims that do not cover their product.
What are the main generic-entry risks for dorzagliatin?
Generic-entry risk is currently low in the near term because dorzagliatin is a recently launched innovative drug and no broad generic market has been established. Risk increases as the core compound patents approach expiry or if secondary patents are weak.
China launch scenarios
| Scenario |
Likely timing |
Commercial effect |
| Protected branded growth |
Before core patent expiry |
Hua Medicine retains pricing and prescriber control |
| Early challenge |
Before expiry through validity or infringement action |
Pricing pressure and litigation expense |
| First generic entry |
After core protection expires |
Rapid erosion in volume and price |
| Formulation-only protection |
After compound expiry |
Partial protection, but broad substitution remains possible |
| Centralized procurement inclusion |
During branded period |
Significant price reduction, potentially higher volume |
China’s centralized procurement system is a major commercial risk. Inclusion can produce substantial price reductions even without generic entry. The drug’s long-term revenue will therefore depend on its clinical differentiation and reimbursement position, not only on patent duration.
What licensing deals affect dorzagliatin?
Hua Medicine entered a strategic collaboration with Bayer relating to dorzagliatin. The partnership was intended to support development and commercialization, particularly in China. Bayer later reduced or ended its involvement in the program, leaving Hua Medicine with greater control over commercialization and a greater share of development and marketing costs.
The transaction history matters for valuation because it indicates that dorzagliatin has attracted multinational pharmaceutical interest but that global commercialization has not yet been validated by a large-scale international launch partner. A new license or co-development agreement outside China would be a material catalyst.
Potential deal structures include:
- Regional licensing for North America.
- Co-development with a diabetes-focused multinational.
- Commercialization rights tied to U.S. or European approval.
- Combination-product development with GLP-1 or insulin therapies.
- Manufacturing partnerships for low-cost Asian markets.
How does dorzagliatin compare with competing diabetes drugs?
Dorzagliatin competes against established therapies rather than only against other glucokinase activators.
| Drug class |
Main advantage |
Main limitation versus dorzagliatin |
| Metformin |
Low cost, broad guideline use |
Gastrointestinal intolerance and limited use in some patients |
| SGLT2 inhibitors |
Cardiovascular and renal outcome benefits |
Genital infections, volume effects and higher cost |
| GLP-1 receptor agonists |
Strong HbA1c and weight reduction |
Injectable delivery, gastrointestinal effects and high cost |
| DPP-4 inhibitors |
Oral dosing and tolerability |
Moderate efficacy and limited weight benefit |
| Sulfonylureas |
Low price and rapid glucose reduction |
Hypoglycemia and weight gain |
| Insulin |
Strong glucose-lowering activity |
Hypoglycemia, injections and treatment burden |
| Dorzagliatin |
Oral glucose-sensing mechanism and low hypoglycemia signal |
Limited global data, uncertain durability and no established cardiovascular-outcome advantage |
Dorzagliatin’s strongest positioning is likely as an oral treatment for earlier-stage type 2 diabetes, especially where beta-cell function remains sufficient. It is less likely to displace GLP-1 receptor agonists in obesity-focused treatment or SGLT2 inhibitors in patients with cardiovascular or renal disease unless outcome data support those uses.
What is the market outlook for dorzagliatin?
The addressable type 2 diabetes population in China is large, but the commercially relevant segment is smaller. It includes patients inadequately controlled on lifestyle intervention or metformin, patients who prefer oral therapy, and patients for whom hypoglycemia avoidance is important.
A practical revenue framework is:
| Scenario |
China peak annual sales |
International contribution |
Main assumptions |
| Downside |
RMB 0.5-1.0 billion |
Minimal |
Narrow label, reimbursement pressure and weak durability |
| Base case |
RMB 1.5-3.0 billion |
RMB 0.5-1.5 billion |
Sustained China adoption and one or more regional approvals |
| Upside |
RMB 4.0-6.0 billion |
RMB 2.0-4.0 billion |
U.S. approval, strong differentiation and multinational partnership |
These are analytical scenarios, not company guidance. The base case assumes that dorzagliatin remains a branded product in China, secures broader physician adoption and receives at least one meaningful international approval. The upside case requires regulatory success outside China and evidence that the drug can compete with modern cardiometabolic therapies.
What will determine commercial performance?
The principal variables are:
- HbA1c durability beyond one year.
- Adoption in combination with metformin.
- Reimbursement and hospital formulary access.
- Price reductions under Chinese procurement programs.
- Safety in patients with reduced renal function or advanced diabetes.
- Evidence of benefit in prediabetes or early beta-cell dysfunction.
- U.S. and European regulatory progress.
- Availability of a commercial partner.
- Manufacturing cost and supply reliability.
What is the revenue exposure to Hua Medicine?
Dorzagliatin is central to Hua Medicine’s commercial profile because the company does not have a diversified portfolio of marketed products comparable with large diabetes companies. This creates high operating leverage.
Positive outcomes can produce rapid revenue growth because the product is already approved in China. The same concentration creates downside risk if reimbursement access is restricted, clinical adoption is slow or the company must fund global trials without a partner.
For investors and potential licensees, the most important commercial metrics are prescription growth, hospital penetration, net price after discounts, patient persistence and selling expense per newly treated patient. Reported gross sales alone may overstate the economic value of the product if government procurement or distributor discounts increase.
What manufacturing and intellectual-property barriers apply?
Dorzagliatin is a small molecule, so it does not face the cell-line, comparability and cold-chain barriers associated with biologics. Generic manufacturing is therefore feasible after relevant compound and process protection expires.
The main manufacturing barriers are:
- Reproducing the required chemical sequence at scale.
- Achieving consistent impurity control.
- Demonstrating bioequivalence for the finished tablet.
- Securing high-quality active pharmaceutical ingredient supply.
- Avoiding infringement of process patents.
- Meeting China, U.S. and European chemistry, manufacturing and controls requirements.
Manufacturing protection is unlikely to replace strong compound protection, but it can delay low-cost competition where the process claims are narrow and difficult to design around.
What generic launch risks exist in the United States and Europe?
No immediate U.S. or European generic launch pathway exists because dorzagliatin is not approved in those markets. If approval occurs, generic competition would likely be delayed by:
- Patent protection for the active compound.
- Regulatory exclusivity associated with a new chemical entity, if applicable.
- Formulation and method-of-use patents.
- Clinical requirements for a generic glucokinase activator.
- Limited commercial incentive before the branded market reaches scale.
The larger near-term risk is regulatory failure or delayed partnering, not generic substitution.
Key Takeaways
- Dorzagliatin is approved in China and is the first marketed glucokinase activator.
- The drug’s strongest near-term opportunity is earlier-line oral treatment for type 2 diabetes.
- No FDA approval, Orange Book listing or U.S. Paragraph IV litigation existed through June 2024.
- The patent estate appears layered, but exact expiry depends on individual families and jurisdictions.
- China reimbursement and centralized procurement pose greater immediate commercial risks than generic entry.
- A U.S. approval or major international licensing transaction would materially improve the valuation case.
- A reasonable long-term revenue range is RMB 1.5 billion to RMB 3.0 billion in the base case, with materially higher results requiring international success.
- Clinical durability, cardiovascular positioning and market access will determine whether dorzagliatin becomes a niche Chinese product or a global diabetes franchise.
FAQs About Dorzagliatin
Is dorzagliatin a GLP-1 drug?
No. Dorzagliatin is a glucokinase activator. It is an oral small molecule and does not act through the GLP-1 receptor.
Can dorzagliatin cause hypoglycemia?
Clinical trials reported a generally low hypoglycemia signal. Risk can still depend on treatment combinations, disease severity, food intake and patient-specific factors.
Is dorzagliatin approved for type 1 diabetes?
No. Its approved indication is type 2 diabetes in China. It is not an insulin replacement and has no established approval for type 1 diabetes.
Will dorzagliatin be included in Chinese centralized procurement?
The timing and terms of any centralized-procurement inclusion depend on Chinese national and provincial policy. Inclusion would likely reduce net price while potentially increasing patient access and volume.
Which companies could compete with dorzagliatin in glucokinase activation?
Potential competition comes from companies developing glucokinase activators, including programs associated with vTv Therapeutics and other diabetes-focused developers. The competitive threat depends on whether those candidates demonstrate durable efficacy and safety superior to earlier GKA programs.
References
-
Hua Medicine. (2022). Annual report 2022. Shanghai, China: Hua Medicine.
-
Hua Medicine. (2023). Annual report 2023. Shanghai, China: Hua Medicine.
-
National Medical Products Administration. (2022). Approval information for dorzagliatin hydrochloride tablets. Beijing, China: NMPA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA.
-
Wang, W., et al. (2022). Efficacy and safety of dorzagliatin in patients with type 2 diabetes inadequately controlled with metformin. The Lancet Diabetes & Endocrinology.
-
International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). Brussels, Belgium: International Diabetes Federation.
